91 results about "Kidney fibrosis" patented technology

The invention relates to the technical field of animal models and concretely, relates to a method for building an animal model with PHF 14 gene knockout-based acute kidney injury and renal fibrosis after injury. The invention builds a model of renal fibrosis after kidney injury under the genetic background of PHF 14 gene knockout under adult conditions and provides essential conditions for researching a use of a PHF 14 gene in fibrotic diseases. Compared with the existing PHF 14 knockout model, the PHF 14 gene knockout provided by the invention does not cause embryonic lethal. A test on adult-stage tamoxifen induced knockout of PHF 14 proves that the PHF 14 gene knockout does not cause embryonic lethal. Compared with a group without knockout, the group subjected to knockout has no substantial pathology of lung, liver and kidney. The method prevents systemic disease state-caused interference on following-up acute kidney injury model making and realizes individual research on use of the gene defect in renal fibrosis pathogenesis.

The invention belongs to the technical field of traditional Chinese medicine sustained-release preparations, in particular to a water-soluble effective component containing centella asiatica for treating trauma, surgical trauma, burns, keloids and scleroderma, antidepressant and treating liver and kidney fibrosis. Centella glycosides) traditional Chinese medicine slow-release preparation and preparation method thereof. The invention adopts the modern preparation technology to compress the traditional Chinese medicine slow-release preparation with solid medicine, skeleton-type auxiliary materials and other excipients. The solid drug refers to the total glycosides of the water-soluble extract of the traditional Chinese medicine Centella asiatica. The total glycosides contain madecassoside and centella asiatica. The total glycosides content in the extract should not be less than 60%. Skeleton-type excipients mainly refer to hydroxypropyl methylcellulose. By adjusting the amount of excipients in the prescription, the release rate of asiaticoside can be controlled, so as to stabilize the blood concentration of the drug, reduce the frequency of medication, and facilitate the use of patients.

The invention belongs to the field of extraction of traditional Chinese medicine, and particularly relates to a cortex eucommiae extract composition for treating renal fibrosis and application of thecortex eucommiae extract composition. The cortex eucommiae extract composition is prepared from the components of aucubin, a mixed extract of geniposide and geniposidic acid, quercetin and chlorogenicacid through the steps of extraction, separation, purification and the like, and the cortex eucommiae extract composition can be further prepared into a preparation. A preparation method is simple and efficient, and the prepared cortex eucommiae extract composition has the good effect of treating renal fibrosis.

The present invention relates to a substance delivery carrier for extracellular matrix-producing cells in the kidney, the carrier including a retinoid as a targeting agent, an agent for treating renal fibrosis utilizing the carrier, a process for producing them, a production kit, a method for treating renal fibrosis using the agent for treating renal fibrosis, etc.

<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.

The invention relates to the technical field of traditional Chinese medicines, in particular to a medicine for treating renal fibrosis and a preparation method thereof. The 31 traditional Chinese medicinal materials provided by the invention have the effects of anti-renal fibrosis, anti-heart-kidney syndrome, anti-heart failure, anti-nephrotic syndrome and / or anti-renal failure medicines; a composition prepared from rhizoma atractylodis macrocephalae, puffball, lysionotus pauciflorus and periostracum cicadae can inhibit renal tubular cell epithelial-mesenchymal transition and inhibit the transcription level of key genes, and therefore renal fibrosis, heart-kidney syndrome, heart failure, nephrotic syndrome and renal failure can be effectively treated.

The invention discloses a traditional Chinese medicine for treating hypertension early-stage kidney damage and a preparation method thereof. The traditional Chinese medicine for treating hypertension early-stage kidney damage disclosed by the invention mainly comprises radix rehmanniae preparata, fructus corni, yam, cortex eucommiae, radix salviae miltiorrhizae and tortoise shell, and is preparedinto various common preparations by the traditional technology of traditional Chinese medicine. The traditional Chinese medicine for treating hypertension early-stage kidney damage disclosed by the invention can effectively relieve the kidney fibrosis progress of the patient suffering hypertension early-stage kidney damage, reduces the kidney burden of the patient, and effectively controls the disease progression; in combination with the oral hypotensor benazepril, a synergistic effect is realized for the blood pressure reducing effect; and compared with the oral hypotensor benazepril only, the traditional Chinese medicine disclosed by the invention takes effect quickly in reducing blood pressure, and the final blood pressure reducing effect is better. Compared with the prior art, the invention has outstanding substantial characteristics and obvious progress.

The invention relates to new application and a new action mechanism of verbascoside, in particular to application of verbascoside in the drugs for treating and preventing type II diabetic nephropathy,and the research on the protection function of the verbascoside for the type II diabetic nephropathy and the action mechanism thereof. Results show that the verbascoside can alleviate liver injury caused by high glucose and lower the serum creatinine, urea nitrogen and urinary microalbuminuria levels, the blood fat level (total cholesterol and triglyceride) and the fasting blood-glucose and bloodinsulin level of spontaneous diabetes db / db mice; TGF (Transforming Growth Factor)-beta 1 and the signal transduction protein Smad3 and Smad4 and alpha-SMA protein expression thereof in a kidney tissue are obviously lowered; meanwhile, the verbascoside can alleviate the liver injury caused by high glucose; HK-2 proliferation and EMT (pithelial-Mesenchymal Transition) formation can be inhibited. In conclusion, the verbascoside has an obvious protection function on the type II diabetic nephropathy, the action mechanism of the verbascoside is that the kidney protection function of the verbascoside is implemented through oxidative stress reaction regulation and control, TGF-beta / smad signaling channel inhibition and kidney fibrosis alleviation.

The present invention relates to a small molecule polypeptide TP-7 having a function of inhibiting a renal fibrosis-promoting function of extracellular matrix tenascin C (TNC) and particularly to a use of the small molecule polypeptide TP-7 in preparation of medicines for treating chronic kidney diseases (CKD). An amino acid sequence of the polypeptide TP-7 is shown in SEQ ID NO.1. In multiple mouse kidney fibrosis models, the TP-7 has a significant effect, can obviously restore renal functions, inhibits progress of renal fibrosis, is also free of obvious toxic and side effects, and thus can be prepared into pharmaceutical preparations for treating the chronic kidney diseases.

The invention discloses a gene capable of enhancing the anti-inflammatory capability of human adipose-derived stem cells (AMSCs) and application of the gene. A nucleotide sequence of the gene is shownas SEQ ID NO: 1. The invention further provides the application of the gene capable of enhancing the anti-inflammatory capability of the human adipose-derived stem cells to a preparation process of amedicine for treating kidney diseases. The gene is a glial cell line-derived neurotrophic factor GDNF. The GDNF modified AMSCs can be used for optimizing the effects of treating kidney fibrosis and delaying a renal failure progress of pure adipose-derived stem cells. According to the gene disclosed by the invention, related researches of the kidney diseases are carried out by applying the GDNF modified AMSCs for the first time, a stem cell therapy method is optimized and a novel thought of traditional cell therapy is explored.

The invention discloses an application of a compound inhibiting dynein light chain roadblock-type 2 in preparation of a medicine treating kidney diseases especially kidney failure diabetes. A knockdown dynein light chain roadblock-type 2 plasmid is used for preparing the medicine. A medicine for treating diabetic nephropathy is also disclosed and comprises the knockdown dynein light chain roadblock-type 2 plasmid. The medicine can be used for achieving novel, safe, effective and controllable gene therapy methods and for inhibiting TGF-beta mediated kidney fibrosis.

The invention discloses application of a fusion polypeptide with multifunctional activity. The fusion polypeptide with multifunctional activity is characterized in that the polypeptide comprises any one of the following structural domains: Pro-Arg-Cys-X-Y-Gly-Glu, wherein X is Trp or Tyr and Y is Arg or Cys; Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. Various fibrotic diseases and symptoms can be treated, including lung fibrosis, liver fibrosis, skin fibrosis, kidney fibrosis and myocardial fibrosis, as well as lung tissue disorders.

The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein the anti-angiogenic activity of the composition is separate from the vascular leakage inhibiting activity of the composition. The animal experiencing at least one of vascular leakage, inflammation and fibrosis has a disease selected from the group consisting of diabetes, chronic inflammation, brain edema, arthritis, uvietis, macular edema, cancer, hyperglycemia, a kidney inflammatory disease, a disorder resulting in kidney fibrosis, a disorder of the kidney resulting in proteinuria, and combinations thereof. The composition capable of inhibiting at least one of vascular leakage, inflammation and fibrosis is selected from the group consisting of angiostatin, fragments of angiostatin, analogs or derivatives of angiostatin, pigment epithelium-derived factor, fragments of pigment epithelium-derived factor, analogs or derivatives of pigment epithelium-derived factor and combinations thereof.

The invention belongs to the technical field of medicine, and relates to application of a prazole compound in preparation of drugs for prevention and treatment of fibrotic diseases. The pantozol compound is pantoprazole, lansoprazole, omeprazole, eprazole, esomeprazole, rabeprazole and other benzimidazole and pyridine substituted sulfoxide compounds or their derivatives. The fibrotic diseases include lung fibrosis, liver fibrosis, kidney fibrosis, heart fibrosis, endometrial fibrosis, eye fibrosis, pancreas fibrosis, spleen fibroplasia, bone marrow fibrosis, skin fibrosis or diseases induced by fibrosis. The prazole compound can be combined with one or more pharmaceutical carriers to form a pharmaceutical composition. The prazole compound or the pharmaceutical composition thereof can be used alone or in combination with other drugs. Moreover, the prazole compound has the advantages of having an obvious curative effect, few side effects and safe use in the treatment of the fibrotic diseases.

Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure:in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2 / Smad3 signaling pathway.

The invention discloses a ureter ligation induced non-human primate animal renal fibrosis model building method and application. The specific technical scheme includes that an experimental monkey is anaesthetized by anesthetics, surgical anesthesia is maintained, the abdomen of the experimental monkey is cut apart along a medioventral line after disinfection, an abdominal cavity is opened, an operation field is exposed, a unilateral ureter at a unilateral renal lower edge is ligated twice by a surgical silk thread and completely blocked, another kidney is not ligated and serves as a self-body for comparison, a wound is stitched in a layered manner after a surgical incision is disinfected, renal fibrosis indexes are measured by biological samples at different time points after ligation, or a left kidney and a right kidney are taken down and fixed in neutral buffered formalin, and formalin fixed kidney samples are subjected to tissue section and pathological examination. An animal model has application values which cannot be realized by an existing rodent and rabbit animal model, and the non-human primate animal model built by the method has wide application in related fields of fibrosis.

The invention provides application of FG4592 in preparation of a medicine for preventing and treating chronic kidney diseases caused by ischemia-reperfusion injury. The application is characterized in that a new candidate compound is provided for the chronic kidney diseases caused by the ischemia-reperfusion injury; the FG4592 is an HIF prolyl hydroxylase activity inhibitor. In addition, the FG4592 can be prepared into a composition of the medicine for the chronic kidney diseases. Specifically, the FG4592 can promote neogenesis of kidney blood vessels, relieve the kidney oxidative stress caused by the ischemia-reperfusion injury and reduce the kidney fibrosis level. The application range of the FG4592 is expanded; the FG4592 is used as the candidate compound for preventing and treating the chronic kidney diseases caused by the ischemia-reperfusion injury to be developed and applied.

The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.

The invention provides the application of rosmarinic acid for preparing medicine that treats or prevents liver and kidney fibrosis. The medicine can be oral liquid or injection, and the dosage for injection is 50 -1500mg, and for oral liquid is 100-3000mg.

New therapeutic use of Polypodium extract. A new use of Polypodacea genus extracts is described for the treatment of fibrotic pathologies, such as, scleroderma, pulmonary fibrosis, atherosclerosis, bone marrow fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, Dupuytrem's disease and, specially, Peyronie's disease; said fibrotic pathologies are produced by an extracellular matriz (ECM) overexpresion, and by a Transforming Growth Factor (TFG-β) overexpression. It is disclosed extracellular matriz inhibition in vitro; and penis tunica albuginea reduction and plaque redution in patients who suffer Peyronie's diseaseas after Polypodium extracts administration. In a preferred mode, Polypodium extracts are obtained from Polypodium leucotomos rhizomes and extraction with a polar solvent.

The invention belongs to the technical field of preparation of novel compounds, and particularly relates to an amide pentaacetyl geniposide derivative as well as a preparation method and application thereof. The amide penta-acetyl geniposide derivative provided by the invention is prepared by the following steps: firstly, hydrolyzing lipid groups at C-4 sites of iridoid in geniposide to obtain geniposidic acid, then acetylating five hydroxyl groups at 2 ', 3', 4 ', 6' and 11 sites on sugar to obtain penta-acetyl geniposidic acid (2a), and finally reacting with RNH2 to obtain the penta-acetyl geniposide derivative. The geniposide derivative prepared by the invention has remarkable XOD inhibitory activity and kidney injury improvement activity, and can effectively reduce the accumulation of uric acid in the kidney. The inflammatory reaction is reduced, so that the level of inflammatory factors is reduced; renal fibrosis of a mouse with hyperuricemia can be reduced by inhibiting expression of an inflammatory factor TGF-beta.

The invention relates to application of sinomenine hydrochloride in promoting apoptosis of mesangial cells. Particularly, sinomenine hydrochloride can alleviate autophagy, proliferation and fibrosis of the mesangial cells caused by LPS. A combination of sinomenine hydrochloride and an autophagy inhibitor can promote the apoptosis of the mesangial cells. According to the application of sinomenine hydrochloride and the application of the combination of sinomenine hydrochloride and the autophagy inhibitor, a research basis is provided for combined treatment of kidney fibrosis disease through Chinese and Western medicine, and a good clinical application prospect is achieved.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry and specifically relates to an O-(1H-tetrazolyl) ethyl derivative of cleistanone, a preparation method and application thereof in preparation of medicines for treating or preventing renal fibrosis. The invention synthesizes a new O-(1H-tetrazolyl) ethyl derivative of cleistanone and discloses the preparation method thereof. Pharmacological experiments show that the O-(1H-tetrazolyl) ethyl derivative of cleistanone has an effect for preventing or treating the renal fibrosis and has the value of developing the medicines for preventing or treating the renal fibrosis.

The invention belongs to the technical field of novel compound preparation, and particularly relates to an ester pentaacetyl geniposide derivative obtained through esterification reaction and a preparation method and application thereof. The amide penta-acetyl geniposide derivative provided by the invention is prepared by the following steps: firstly, hydrolyzing lipid groups at C-4 sites of iridoid in geniposide to obtain geniposidic acid, then acetylating five hydroxyl groups at 2 ', 3', 4 ', 6' and 11 sites on sugar to obtain penta-acetyl geniposidic acid (2a), and finally reacting with ROH to obtain the penta-acetyl geniposide derivative. The geniposide derivative prepared by the invention has remarkable XOD inhibitory activity and kidney injury improvement activity, and can effectively reduce the accumulation of uric acid in the kidney. The inflammatory reaction is reduced, so that the level of inflammatory factors is reduced; renal fibrosis of a mouse with hyperuricemia can be reduced by inhibiting expression of an inflammatory factor TGF-beta.

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.

The present invention relates to a medical use of natural cyclic heptapeptide molecule microcystin-RR in preventing and treating renal fibrosis diseases. The verified microcystin-RR is themicrocystinof which the second and fourth amino acids of the cyclic heptapeptide structure are arginine. The microcystin RR has prevention and treatment effects on pathogenesis of the renal fibrosis caused by ureteral obstruction. Microcystin RR intervention can change kidney tissue microenvironment caused by the ureteral obstruction, inhibit fibroblast-myofibroblast differentiation (FMD) of kidney tissue cells and generate an anti-renal fibrosis medical effect.

The invention provides a structural sequence and a construction method of a fused polypeptide mutant containing a protein transduction domain TAT (Transactivator of Transcription), a Smad anchor and a receptor-activated protein SARA peptide aptamer (SARA / SBD). The fused protein mutant contains 73 amino acids. The protein is subjected to fusion expression and purification, and purified TAT-SARA / SBD is taken as a tested medicament for performing an animal single-side ureteral ligation obstruction model experiment. As proved by a result, the tested medicament has a fibrosis reversing effect. The fused protein mutant can be subjected to efficient supernatant expression, is easy for purifying, is convenient for roducing, and is expected to be applied to treatment of kidney fibrosis.

The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.